What is Veritas Intercontinental?
Veritas Intercontinental operates at the intersection of advanced biotechnology and machine learning, positioning itself as a premier provider of comprehensive genetic services. Founded in 2018 as an extension of the broader Veritas brand, the company leverages the foundational research of visionaries like George Church to offer a robust portfolio, including the myGenome service and specialized maternal-fetal genetic testing. By integrating AI-driven interpretation with rigorous clinical standards, Veritas Intercontinental bridges the gap between raw genomic sequencing and personalized medical decision-making, serving both healthcare providers and individual patients with high-precision diagnostic tools.
How much funding has Veritas Intercontinental raised?
Veritas Intercontinental has raised a total of $8.8M across 2 funding rounds:
Series A
$3M
Series B
$5.8M
Series A (2009): $3M with participation from Ascent Venture Partners and Cedar fund
Series B (2020): $5.9M led by Graham Snudden, Amadeus Capital Partners, Charme Capital Partners, and Stemar Capital Partners
Key Investors in Veritas Intercontinental
Amadeus Capital Partners
Amadeus Capital Partners is a London-based global technology venture capital firm that invests in high-growth companies from seed to later stages across sectors such as artificial intelligence, digital health, cybersecurity, enterprise software, fintech, and deep tech.
Charme Capital Partners
A pan-European mid-market private equity firm that focuses on supporting the growth and internationalization of companies with strong competitive advantages.
Ascent Venture Partners
A venture capital firm specializing in early-stage investments in information technology and software-driven businesses that demonstrate significant market disruption potential.
What's next for Veritas Intercontinental?
With the recent strategic financing, Veritas Intercontinental is poised to accelerate its operational footprint and deepen its integration into global healthcare systems. The company's roadmap focuses on the continuous evolution of its diagnostic portfolio, ensuring that its clinical services remain at the forefront of scientific discovery. By prioritizing research-backed innovation and expanding its laboratory capacity, Veritas aims to democratize access to genomic information, ultimately enhancing the quality and longevity of patient lives through data-driven wellness and preventative care strategies.
See full Veritas Intercontinental company page
